Hello, everyone, and how are you this morning? Despite the chaos, we are hanging in there, as they say. Our short person is busy learning at home and our new official mascot is scurrying about as he becomes acquainted with the Pharmalot campus. As for us, we are attempting to go about our usual routine, which includes a cup of stimulation and gazing out the window at delightfully sunny skies. Now, though, the time has come to get cracking. So here are a few items of interest to help you along. Hope your days goes well and you stay healthy.

At least four state pharmacy boards took steps to limit prescriptions of potential coronavirus treatments touted by President Trump that are in short supply as demand has surged with the rapid spread of the outbreak, Reuters says. Boards in Texas, Ohio, Idaho, and Nevada in recent days moved to restrict who can be prescribed the malaria treatments chloroquine and hydroxychloroquine, and how much of the drugs can be prescribed. Texas has also limited prescriptions of the antibiotic azithromycin as well as another anti-malarial drug, mefloquine.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy